OCT 5·SEC EDGARLow
STARR CHRISTOPHER M sold $659K of MNPR
STARR CHRISTOPHER M sold 8,400 shares of Monopar Therapeutics (MNPR) at an average of $78.50 ($78.09–$79.67, $0.66M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$MNPR
Monopar Therapeutics
Price · $MNPRvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $MNPR in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $3.2M 7 txs
Robinson Chandler4× · $2.6M
10b5-1 share of filings100%
Top stories · $MNPRMore →
SEP 29·SEC EDGAR
Robinson Chandler sold $2.6M of MNPR
Robinson Chandler (Chief Executive Officer) sold 29,056 shares of Monopar Therapeutics (MNPR) at an average of $88.00 ($87.15–$89.79, $2.56M total) across 4 trades on 2026-09-24 under a Rule 10b5-1 trading plan.
AUG 19·rttnews.com
MNPR Names New Medical Affairs Head As ALXN1840 Advances Toward FDA Decision
Monopar Therapeutics (MNPR) appointed Jeffrey D. Kent as EVP and Head of Medical Affairs. The company is preparing for a potential U.S. launch of ALXN1840 for Wilson disease, with two abstracts accepted for presentation at AASLD 2026. ALXN1840's Phase 3 trial met its primary endpoint. MNPR's stock closed at $119, up 2.20%, and is down 0.05% in premarket trading.
MNPR sentiment & insider activity
Recent MNPR coverage spans insider activity, sector analysis and market movers.
In the last 30 days, MNPR insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($3.2M). The most active reporter was Robinson Chandler, Chief Executive Officer, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving MNPR
The insider sale may signal reduced confidence and could weigh on the stock.
Insider sale suggests potential downside pressure on MNPR.
Executive hire signals continued focus on the ALXN1840 Wilson disease program and may support upcoming FDA filing and launch.
This is a primary earnings-style disclosure (Q2 results) but the scraped text does not include the actual financial figures or guidance, limiting actionable signal.
Rolling NDA submission is a meaningful regulatory milestone that can improve approval odds and de-risk the path to a first-in-class Wilson disease therapy.
AlphAI scores every news story that mentions MNPR with an AI model for sentiment and relevance, and aggregates insider trades from Monopar Therapeutics's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $MNPR
Score
STARR CHRISTOPHER M sold $659K of MNPR
STARR CHRISTOPHER M sold 8,400 shares of Monopar Therapeutics (MNPR) at an average of $78.50 ($78.09–$79.67, $0.66M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readRobinson Chandler sold $2.6M of MNPR
Robinson Chandler (Chief Executive Officer) sold 29,056 shares of Monopar Therapeutics (MNPR) at an average of $88.00 ($87.15–$89.79, $2.56M total) across 4 trades on 2026-09-24 under a Rule 10b5-1 trading plan.
1 min readMNPR Names New Medical Affairs Head As ALXN1840 Advances Toward FDA Decision
Monopar Therapeutics (MNPR) appointed Jeffrey D. Kent as EVP and Head of Medical Affairs. The company is preparing for a potential U.S. launch of ALXN1840 for Wilson disease, with two abstracts accepted for presentation at AASLD 2026. ALXN1840's Phase 3 trial met its primary endpoint. MNPR's stock closed at $119, up 2.20%, and is down 0.05% in premarket trading.
1 min readMonopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr
2 min readMonopar Therapeutics Inc.: Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Monopar Therapeutics (Nasdaq: MNPR) said the FDA authorized it to initiate a rolling NDA submission for ALXN1840 (tiomolibdate choline, TMC) for Wilson disease. The company submitted the first completed NDA sections. ALXN1840 has Fast Track and Orphan Drug designations and received Rare Pediatric Disease status in June 2026.
2 min readBiotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS
Biotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.
4 min readBiotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT
Biotech stocks hit 52-week highs on July 9, 2026. First Track Biotherapeutics (TRAX) rose 55.99% to $32.40 on Phase 1 trial starts and an FDA end-of-Phase 2 meeting. BridgeBio Pharma (BBIO) closed at $93.52, up 15.12%, citing Acoramidis and Phase 3 plans. Monopar (MNPR), 10x Genomics (TXG) and MapLight (MPLT) also reached highs amid clinical updates.
6 min readTop Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment
Boundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min readMonopar Therapeutics (MNPR): Submission of Matters to a Vote of Security Holders
Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. mnpr20260622_8k.htm false 0001645469 0001645469 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
2 min read
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.
4 min read